Coffey lab awarded 360,000$ from Michael J. Fox Foundation to Improve Patient Diagnosis and Monitoring in Parkinson’s Disease
The lab identified that LRRK2, a kinase that plays a central role in familial and sporadic Parkinson’s Disease, controls the cellular machinery that is responsible for translating genetic code into proteins. This machinery is called the ribosome. They found that the production of new proteins by ribosomes was lower in rodent models of Parkinson’s disease and in skin biopsies from patients with sporadic disease or from those carrying a specific mutation in LRRK2. With this funding the group will search for disease-specific signatures of disturbed ribosome function from patient blood. Demonstration of patterns of proteins that are robust markers of Parkinson’s disease and especially of disease progression will allow diagnosis and staging. The proteins identified may also give useful insight on disease mechanism.
The Michael J. Fox Foundation supports research towards altering and defining Parkinson’s disease. This work is in collaboration with Prof. Peter James at the University of Lund and Dr. Valtteri Kaasinen at Turku University Hospital.
Recent Posts
- New computational tool helps scientists interpret complex single-cell data Researchers from Laura Elo’s group, have developed a new computational method to interpret complex single-cell Read moreNovember 17, 2025
- Carlos Rogério Figueiredo received the Young Investigator Award Carlos Rogério Figueiredo has received the Young Investigator Award from the Scandinavian Society for Immunology. Read moreNovember 4, 2025
- Participate to Open Hardware Workshop, sign up now! Access to research hardware remains a global challenge and it impacts also researchers in high-income Read moreNovember 3, 2025
- The Academy of Finland granted Johanna Ivaska €2,400,000 in funding for an Academy Professor position The Academy of Finland granted our Group Leader, Professor Johanna Ivaska €2,400,000 in funding for Read moreOctober 30, 2025
- Guillaume Jacquemet and Cecilia Sahlgren receive funding for the Research Council of Finland Centre of Excellence in Immune-Endothelial Interactions (IMMENs) Associate Professor Guillaume Jacquemet, our Group Leader, and Professor Cecilia Sahlgren, our affiliated Group Leader, Read moreOctober 30, 2025
- Registration to AI2Med imaging event is now open! Registration for AI2Med Turku 2025 is open! The event is organized by the Turku PET Read moreOctober 21, 2025